Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

d in addition to, and not in lieu of, U.S. GAAP financial measures. The Company's non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward- looking and, as such, are subject to risks and uncertainties, including the extent and impact of litigation arising out of the accounting issues described in the Company's filings with the Securities and Exchange Commission (SEC), the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against the Company, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the Company's filings with the SEC, such as the Company's reports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Any forward-looking statements included in this press release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

PAR PHARMACEUTICAL COMPANIES, INC.


'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2008)...ts that Cary Hall,s Health Insurance Program Gains...Health Insurance and Health Care Solutions Particu... Kansas City, MO (PRWEB) August 28, 2008 -- The...waves of Springfield, Missouri, on Saturday, Septe... one-hour program will be heard live each Saturday...
(Date:8/27/2008)...re-FirstCall/ -- Replidyne, Inc.,(Nasdaq: RDYN ) ...s reducing,its current employee headcount by appro...heduled to take place during September 2008 and Oc... will suspend further,development activities of RE... of Clostridium difficile (C. difficile) bacteria ...
(Date:8/27/2008)...adiology and Oncology has selected renowned pediat...orary member. Dr. Evans will be recognized during ... 10:00 a.m. during ASTRO,s 50th Annual Meeting in ...he treatment and study of childhood cancer for dec...al Ronald McDonald House, which opened in Philadel...
(Date:8/27/2008)...onger to see positive effect, researchers say , ...he blood pressure drug telmisartan does not lower ...tes better than a placebo in patients who have had...an angiotensin II receptor blocker, which works by...he blood vessels enabling the blood to flow more s...
Breaking Medicine News(10 mins):Health News:The Health Insurance Advocate Radio Show Expands to Springfield, Missouri, and Reaches a New All-Time Ratings High for Female Listenership 2Health News:The Health Insurance Advocate Radio Show Expands to Springfield, Missouri, and Reaches a New All-Time Ratings High for Female Listenership 3Health News:Replidyne Announces Restructuring of Operations 2Health News:ASTRO selects pediatric oncologist as 2008 honorary member 2Health News:Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke 2Health News:Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke 3
...ed a bill that seeks to regulate private health se...bind private health clinics to discharge both insu...Entremont says private facilities will be able to ...es. Besides the legislation will also include a co...
...e zeroed in on cardiac master cells that could dev...iscovered by different groups of researchers who h...ver two basic contenders. Research teams from Mas...nized a variety of progenitor cell in mice, and ha...
...Minister for Ageing, Senator Santo Santoro, to dis...es, //as set out in the AMA's Federal Budget Submi...care Benefits Schedule (MBS) makes it very difficu...ng care to residents of aged care facilities. AM...
...bout the side effects associated with using birth ...evelopment of severe blood clots in the lungs and...iol is available in the U.S with more of the comp...e of this birth control patch has been linked with...
Other Medicine News:
(Date:8/27/2008)... Memorial Hospital one of 18 centers involved in 1...wire/ -- Results of a 10-year study,published in t...edicine,found that magnesium sulfate administered ...educed the risk of cerebral palsy by 50 percent. T...te (BEAM) trial was,conducted in 18 centers in the...
(Date:8/27/2008)...rance, August 27 /-, - Ora...ults in a,Pharmacodynamic Study Conducted in an Al...nces the highly positive results of a new study,co...The study on Oralair(R) Grasses included 86 adult ...fferent treatment durations: 1 week, 1 month,2 an...
(Date:8/26/2008)...e., Aug. 26 /- The Oregon Tourism Com...Customer Service Training Program,(Q Care) this we...e is a training program created to support the tou...loyee education. By emphasizing,the importance of ...employees with tools and resources to better serve...
(Date:8/26/2008)...LIS, Aug. 26 /- Semafore Pharmaceutic...al Congress on Targeted Therapies,in Cancer in Was...ulti-targeted kinase inhibitors that demonstrate s...ies., A novel and proprietary molecular scaffold ...lowing for the design of pan-PI3 kinase inhibitors...
Breaking Medicine Technology:National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births 2National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births 3Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Oregon Tourism Commission Unveils New Online Customer Service Training Program 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3OncoGenex reports lead drug candidate OGX 011 achieved primary endpoint in Phase 2 Trial with second line chemotherapy for prostate cancer 3335 1OncoGenex reports lead drug candidate OGX 011 achieved primary endpoint in Phase 2 Trial with second line chemotherapy for prostate cancer 3335 2OncoGenex reports lead drug candidate OGX 011 achieved primary endpoint in Phase 2 Trial with second line chemotherapy for prostate cancer 3335 3OncoGenex reports lead drug candidate OGX 011 achieved primary endpoint in Phase 2 Trial with second line chemotherapy for prostate cancer 3335 4Hcareers com Strengthens Local Market Candidate Reach Through RegionalHelpWanted com Acquisition 3333 1Hcareers com Strengthens Local Market Candidate Reach Through RegionalHelpWanted com Acquisition 3333 2Poniard Pharmaceuticals Announces Positive First line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 1377 1Poniard Pharmaceuticals Announces Positive First line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 1377 2Poniard Pharmaceuticals Announces Positive First line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 1377 3Poniard Pharmaceuticals Announces Positive First line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 1377 4Poniard Pharmaceuticals Announces Positive First line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 1377 5Learning Takes Center Stage at My Urban Toddler 12019 1Learning Takes Center Stage at My Urban Toddler 12019 2
... Proprietary EX.P.R.T. Release Technology essent...,, No stent shortening,, Unique anatom...e carotid bifurcation,, 0.014 Rapid Exchang...ible atraumatic tip,, Radiopaque marker on ...
From top to bottom, EZ STEER Bi-Directional Catheters put amazing responsiveness, predictability, and comfort close at hand. Utilizing a patented Biosense Webster micro-tensioning system that enables
... STaK-Chex, a whole blood assayed hematology contr... white cell differential available with the Coulte...s 14-day open-vial stability, 105-day closed-vial ... levels. The 4.0ml pierceable cap vial is compatib...
The Pilot® thoracolumbar pedicle screw system has been engineered to deliver implants safely and quickly while maximizing versatility. Whether instrumenting through an open procedure or through
Medicine Products: